Rashaan R, Arkoumanis P T
Dermatology Department, Guys and St. Thomas Hospital, London Bridge road, London, United Kingdom.
Plastic and Reconstructive Surgery Department, General Hospital of Attica "KAT", 2 Nikis 14561, Athens, Greece.
Maedica (Bucur). 2023 Dec;18(4):712-717. doi: 10.26574/maedica.2023.18.4.712.
Palmar hyperhidrosis, a condition characterized by excessive sweating in the palms, considerably impacts the quality of life (QoL). Although various treatment modalities are available, the efficacy and safety of Botulinum toxin type A (BTX-A) needed further investigation. We conducted a literature review, with open-label, controlled trial, double-blind placebo-controlled and observational designs being eligible for inclusion, according to the PRISMA guidelines. All the six selected studies consistently reported the efficacy of BTX-A in reducing symptoms of hyperhidrosis, without significant side effects. Botulinum toxin type A treatment was found to improve the QoL significantly, to reduce sweat rate and production and to have no detrimental effect on grip strength. The duration of the antisudorific effect also indicated the potential for long-term management of palmar hyperhidrosis with BTX-A. Our findings corroborated the effectiveness and safety of BTX-A in managing palmar hyperhidrosis across diverse patient outcomes and experiences. Botulinum toxin type A emerged as a promising treatment modality for this condition, capable of improving the QoL, reducing symptoms and offering long-term relief without significant side effects.
掌部多汗症是一种以手掌过度出汗为特征的病症,严重影响生活质量(QoL)。尽管有多种治疗方式可供选择,但A型肉毒杆菌毒素(BTX-A)的疗效和安全性仍需进一步研究。根据PRISMA指南,我们进行了一项文献综述,纳入了开放标签、对照试验、双盲安慰剂对照和观察性设计的研究。所有六项入选研究均一致报告了BTX-A在减轻多汗症症状方面的疗效,且无明显副作用。研究发现,A型肉毒杆菌毒素治疗可显著改善生活质量,降低出汗率和汗液分泌量,且对握力无不利影响。止汗效果的持续时间也表明了BTX-A对掌部多汗症进行长期管理的潜力。我们的研究结果证实了BTX-A在管理掌部多汗症方面的有效性和安全性,涵盖了不同的患者结局和体验。A型肉毒杆菌毒素成为了治疗这种病症的一种有前景的治疗方式,能够改善生活质量、减轻症状并提供长期缓解且无明显副作用。